Court Rules Apotex, Cobalt Infringe Roche's Boniva Patent
This article was originally published in The Pink Sheet Daily
A New Jersey district court judge trounces the generic manufacturers' claim that the salt of the drug's active ingredient is not physiologically active.
You may also be interested in...
Orchid's revised patent certification against the osteoporosis drug ibandronate allows Roche to block approval until March 2012.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.